S2Medical AB Class B (SE:S2M)
:S2M
Top Page
S2Medical AB Class B
(S2M)
Select Model
Select Model
Rating:51Neutral
Price Target:
kr0.01
▲(10.00% Upside)
Action:ReiteratedDate:02/24/26
The score is held back primarily by weak and unstable financial performance, including the sharp 2025 reversal into significant losses and uneven cash flow durability, despite a low-debt balance sheet. Technical indicators provide partial support with improving near-term momentum, while valuation cannot be meaningfully assessed due to missing P/E and dividend data.
Positive Factors
Low leverage / conservative balance sheet
Minimal debt provides durable financial flexibility for a small medical-instruments company. Low leverage reduces refinancing and interest-risk, enabling management to prioritize product development, regulatory compliance and selective investment during downturns without immediate external funding needs.
Negative Factors
Highly volatile profitability and margin swings
Large, rapid swings in revenue and margins indicate the company lacks stable, diversified revenue streams or consistent pricing power. Persistent volatility undermines planning, erodes equity in downturns, and makes sustaining R&D, regulatory and commercial investments risky over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / conservative balance sheet
Minimal debt provides durable financial flexibility for a small medical-instruments company. Low leverage reduces refinancing and interest-risk, enabling management to prioritize product development, regulatory compliance and selective investment during downturns without immediate external funding needs.
Read all positive factors
S2Medical AB Class B (S2M) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr7.98M
Dividend YieldN/A
Average Volume (3M)2.90M
Price to Earnings (P/E)―
Beta (1Y)0.61
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees17
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.01
Shares Outstanding898,657,040
10 Day Avg. Volume1,954,268
30 Day Avg. Volume2,901,877
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.93
Price to Sales (P/S)0.64
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr60.00M
S2Medical AB Class B Business Overview & Revenue Model
Company Description
S2Medical AB (publ) develops, produces, and sells wound healing products for burns and chronic wounds. It offers INSTAQRETT, a sterile single use mechanical debridement tool; EPIPROTECT SafeStop for blood stilling; Instagraft, a single-use medical...
How the Company Makes Money
S2Medical AB generates revenue primarily through the sale of its advanced wound care products to hospitals, clinics, and other healthcare providers. The company's revenue model is based on direct sales, as well as partnerships and distribution agr...
S2Medical AB Class B Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
63
Positive
Cash Flow
35
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.46M | 14.36M | 14.91M | 6.97M | 4.67M | 7.70M |
| Gross Profit | 16.72M | -2.68M | 14.14M | 5.04M | 5.17M | 7.10M |
| EBITDA | -3.71M | -1.41M | 6.82M | -13.53M | -26.37M | -18.73M |
| Net Income | -3.62M | -10.09M | 5.77M | -22.71M | -29.46M | -20.08M |
Balance Sheet | ||||||
| Total Assets | 25.96M | 16.78M | 18.09M | 21.41M | 25.29M | 29.68M |
| Cash, Cash Equivalents and Short-Term Investments | 1.29M | 907.00K | 1.00M | 1.52M | 3.72M | 9.48M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 207.69K |
| Total Liabilities | 7.08M | 6.90M | 6.29M | 19.75M | 18.22M | 15.00M |
| Stockholders Equity | 18.88M | 9.88M | 11.80M | 1.66M | 7.07M | 14.68M |
Cash Flow | ||||||
| Free Cash Flow | 5.85M | 0.00 | 2.49M | -17.67M | -30.03M | -22.76M |
| Operating Cash Flow | 6.85M | 675.00K | 3.12M | -16.52M | -28.13M | -19.67M |
| Investing Cash Flow | -1.09M | -2.02M | -634.00K | -1.15M | -1.76M | -3.02M |
| Financing Cash Flow | -5.71M | 1.25M | -5.54M | 15.47M | 24.14M | 6.85M |
S2Medical AB Class B Technical Analysis
Negative
0.01
Price Trends
0.01
Negative
0.01
Negative
0.01
Negative
Market Momentum
>-0.01
Positive
44.62
Neutral
20.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:S2M, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.62 is Neutral, neither overbought nor oversold. The STOCH value of 20.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:S2M.
S2Medical AB Class B Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | kr7.98M | -0.91 | ― | ― | ― | ― | |
44 Neutral | kr147.71M | -1.48 | -52.45% | ― | 2.56% | 52.76% | |
43 Neutral | kr48.50M | -1.14 | -50.21% | ― | ― | -108.64% | |
43 Neutral | kr42.77M | -1.97 | ― | 8.47% | -94.12% | -25.83% |
* Healthcare Sector Average
SE:S2M
S2Medical AB Class B
0.01
>-0.01
-16.67%
SE:SPEC
SpectraCure AB
0.09
-0.66
-88.62%
SE:NXTCL
NextCell Pharma AB
1.33
0.26
23.93%
SE:LARK
CombiGene AB
2.16
-0.03
-1.32%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.